Panacea Biotec is set to convene a board meeting on May 29, 2026, for the approval of their FY26 audited financial results. Shareholders should note that dividend-related matters and trading windows will be closed until May 31, 2026. Stay tuned for further updates post the meeting.

Panacea Biotec has experienced a significant breakthrough, surpassing its 50-week moving average in a descending triangle pattern. This move is supported by an uptrend in the Relative Strength Index (RSI), suggesting the stock's momentum could be strengthening. The increased trading volume and prolonged consolidation further indicate a potentially positive outlook for Panacea Biotec's share price.

Panacea Biotec experiences a temporary halt in operations at their Baddi oncology lab due to a short circuit-related fire. The situation has been brought under control but may last for 5-7 days, with insurance covering the incident.

Panacea Biotec has secured a significant tax break of INR 9.16 crore, as the ITAT has overturned a demand from AY 2020-21. The ruling also dismisses a disallowed expense addition worth INR 3.44 crore under Section 14A and imposes no penalties on the company.

Panacea Biotec has secured a significant government contract for the supply of Diphtheria and Tetanus vaccines, extending their delivery period up to December 2028 in multiple phases starting from September-October 2026.

Panacea Biotec secures a significant INR 20.79 crore order from CMSS for the supply of Td vaccines, scheduled for delivery between September 2026 and December 2028. Notably, there are no related party transactions involved in this deal.

Panacea Biotec has secured a Letter of Award worth INR 20.79 crore from the Central Medical Services Society, marking a significant new government order for the company.

According to a recent rectified order, the income tax demand on Panacea Biotec Ltd has been significantly reduced from 457.1 million rupees to zero, marking a substantial relief for the company.

Panacea Biotec has been issued a GST demand of approximately INR 22.9 crore, including penalties, for the period April 2019 to March 2022. However, the company has managed to secure an interim stay following a writ petition, which means no immediate financial or operational impact is expected.